Prostate Cancer International is
for 2011 by Great NonProfits
According to a company media release, the full results of the ALSYMPCA trial were presented Saturday at the European Multidisciplinary Cancer Congress (EMCC). This is the trial of the injectable radioactive agent radium-223 chloride (Alpharadin®) in men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: Alpharadin, outcome, radium, radium-223, survival | Leave a Comment »
The Phase III SATURN clinical trial of OGX-011 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after initial chemotherapy with docetaxel + prednisone required men to be randomized to either docetaxel + prednisone + OGX-011 or to docetaxel + prednisone + a placebo.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, custirsen, docetaxel, OGX-011, pain, SATURN, survival, synergy | Leave a Comment »
As we have noted several times before, databases in selected European nations (most particularly the Scandinavian countries) allow for the possibility of highly accurate analyses of information on the diagnosis, management, and outcomes of prostate cancer (and other disorders) over time based on data from very large numbers of people.
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Denmark, Diagnosis, mortality, outcome, survival | 3 Comments »
As we have previously reported, the latest analysis of survival data from the pivotal Phase III trial of abiraterone acetate + predisone has shown a slight improvement in the survival benefit for patients treated with abiraterone (Zytiga™).
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, circulating tumor cell, CTC, survival, Zytiga | Leave a Comment »
A story on the Bloomberg.com web site gives information about a patient with castration-resistant prostate cancer (CRPC) who has had a zero-level PSA for 40 months since starting on a clinical trial of abiraterone actetate in early 2008.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, CRPC, orteronel, survival, TAK-700 | 3 Comments »
We have already noted the FDA’s approval of abiraterone acetate. However, there are some interesting details that are worthy of note.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, approval, survival, Zytiga | 2 Comments »
A new article in Lancet Oncology has reported that a mere 6 months of neoadjuvant hormone therapy, when combined with radiation therapy, cuts the risk of dying from locally advanced prostate cancer by 50 percent compared to radiation alone at 10 years of follow-up.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone, neoadjuvant, outcome, radiation, survival | 12 Comments »
A clear appreciation of the associations between life expectancy, comorbid conditions (e.g., diabetes, obesity, cardiovascular disorders), and mortality is critically important to treatment decisions for all patients with prostate cancer, but most especially the newly diagnosed, low-risk patient.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: comorbidity, outcome, survival, Sweden, Treatment | Leave a Comment »
A study by researchers at the University of Miami and Yale School of Medicine suggests there may be an association between patients’ beliefs about the potential curability of prostate cancer and their overall, long-term survival.
Filed under: Living with Prostate Cancer | Tagged: belief, outcome, survival | 8 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site